1
|
Purks JL, Arbatti L, Hosamath A, Amara AW, Anderson KE, Chahine L, Eberly SW, Kinel D, Mantri S, Mathur S, Oakes D, Standaert DG, Weintraub D, Shoulson I, Marras C. Cognitive Symptoms in Cross-Sectional Parkinson Disease Cohort Evaluated by Human-in-the-Loop Machine Learning and Natural Language Processing. Neurol Clin Pract 2024; 14:e200334. [PMID: 38962394 PMCID: PMC11221914 DOI: 10.1212/cpj.0000000000200334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Accepted: 04/12/2024] [Indexed: 07/05/2024]
Abstract
Background and Objectives Cognitive impairment is experienced by up to 80% of people with Parkinson disease (PD). Little is known regarding the subjective experience and frequency of bothersome cognitive problems across the range of disease duration as expressed directly in patients' own words. We describe the types and frequency of bothersome cognitive symptoms reported verbatim by patients with PD. Methods Through the online Fox Insight study and the Parkinson Disease Patient Report of Problems, we asked patients with PD to self-report by keyboard entry up to five most bothersome problems and how these problems affect their functioning. Human-in-the-loop curation, natural language processing, and machine learning were used to categorize responses into 8 cognitive symptoms: memory, concentration/attention, cognitive slowing, language/word finding, mental alertness/awareness, visuospatial abilities, executive abilities/working memory, and cognitive impairment not otherwise specified. Associations between cognitive symptoms and demographic and disease-related variables were examined in our cross-sectional cohort using multivariate logistic regression. Results Among 25,192 participants (55% men) of median age 67 years and 3 years since diagnosis (YSD), 8,001 (32%) reported a cognitive symptom at baseline. The 3 most frequently reported symptoms were memory (13%), language/word finding (12%), and concentration/attention (9%). Depression was significantly associated with bothersome cognitive problems in all domains except visuospatial abilities. Predictors of reporting any cognitive symptom in PD were depression (adjusted OR 1.5), increasing MDS-UPDRS Part II score (OR 1.4 per 10-point increment), higher education (OR 1.2 per year), and YSD 1, 2, 6-7, and 8-9 vs 0 YSD. Among individuals with at least one cognitive symptom, posterior cortical-related cognitive symptoms (i.e., visuospatial, memory, and language) were reported by 17% (n = 4325), frontostriatal-related symptoms (i.e., executive abilities, concentration/attention) by 7% (n = 1,827), and both by 14.2% (n = 1,020). Odds of reporting posterior cortical symptoms vs frontostriatal symptoms increased with age and MDS-UPDRS part II score, but not depression. Discussion Nearly one-third of participants with PD, even early in the disease course, report cognitive symptoms as among their most bothersome problems. Online verbatim reporting analyzed by human-in-the-loop curation, natural language processing, and machine learning is feasible on a large scale and allows a detailed examination of the nature and distribution of cognitive symptoms in PD.
Collapse
Affiliation(s)
- Jennifer L Purks
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - Lakshmi Arbatti
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - Abhishek Hosamath
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - Amy W Amara
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - Karen E Anderson
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - Lana Chahine
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - Shirley W Eberly
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - Daniel Kinel
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - Sneha Mantri
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - Soania Mathur
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - David Oakes
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - David G Standaert
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - Daniel Weintraub
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - Ira Shoulson
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| | - Connie Marras
- Department of Neurology (JLP, DK, IS), University of Rochester, NY; Grey Matter Technologies (LA, AH, IS), a wholly owned subsidiary of Modality.ai, San Francisco, CA; Department of Neurology (AWA), University of Colorado Anschutz Medical Campus, Aurora; Departments of Psychiatry and Neurology (KEA), Georgetown University, Washington, DC; Department of Neurology (LC), University of Pittsburgh, PA; Department of Biostatistics and Computational Biology (SWE, DO), University of Rochester, NY; Department of Neurology (Sneha Mantri), Duke University, Durham, NC; PD Avengers (Soania Mathur), Toronto, Ontario, Canada; Department of Neurology (DGS), University of Alabama at Birmingham; Departments of Psychiatry and Neurology (DW), Perelman School of Medicine at the University of Pennsylvania, Philadelphia; and Edmond J Safra Program in Parkinson's Disease (CM), University Health Network, University of Toronto, Ontario, Canada
| |
Collapse
|